Bruker’s IsoSpark technology, an advanced single-cell proteomics platform that enables the functional profiling of immune and tumor cells by detecting proteins secreted by individual cells.

Unlike traditional assays, IsoPlexis captures the polyfunctional profile of individual cells, meaning it can simultaneously measure multiple cytokines or chemokines secreted by the same cell. Using a proprietary multiplexed microchamber and antibody array system, the platform analyzes thousands of single cells in parallel, revealing rare but highly functional subsets that determine immune responses or disease progression.

This technology is particularly powerful in immuno-oncology, cell therapy and infectious disease research, where understanding cellular heterogeneity is crucial. By offering a multi-dimensional view of cellular function, IsoPlexis provides in-depth information on immune responses, therapeutic efficacy and disease mechanisms, enabling the discovery of predictive biomarkers and guiding personalized treatment strategies.